Moody National Bank Trust Division Has $4.66 Million Position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)


Share on StockTwits

Moody National Bank Trust Division reduced its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 3.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,472 shares of the biopharmaceutical company’s stock after selling 930 shares during the period. Moody National Bank Trust Division’s holdings in Alexion Pharmaceuticals were worth $4,660,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Roberts Glore & Co. Inc. IL lifted its holdings in Alexion Pharmaceuticals by 1.8% during the 4th quarter. Roberts Glore & Co. Inc. IL now owns 3,694 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 65 shares during the last quarter. Eudaimonia Partners LLC lifted its holdings in Alexion Pharmaceuticals by 37.1% during the 3rd quarter. Eudaimonia Partners LLC now owns 288 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 78 shares during the last quarter. CX Institutional lifted its holdings in Alexion Pharmaceuticals by 41.9% during the 4th quarter. CX Institutional now owns 264 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 78 shares during the last quarter. RNC Capital Management LLC lifted its holdings in Alexion Pharmaceuticals by 0.4% during the 4th quarter. RNC Capital Management LLC now owns 21,919 shares of the biopharmaceutical company’s stock worth $3,425,000 after purchasing an additional 86 shares during the last quarter. Finally, Allstate Corp lifted its holdings in Alexion Pharmaceuticals by 4.8% during the 4th quarter. Allstate Corp now owns 1,897 shares of the biopharmaceutical company’s stock worth $296,000 after purchasing an additional 87 shares during the last quarter. 87.27% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on ALXN. Raymond James lowered Alexion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, January 8th. SVB Leerink restated a “market perform” rating and set a $156.00 price objective (down previously from $196.00) on shares of Alexion Pharmaceuticals in a research note on Monday, March 29th. Finally, Piper Sandler lowered Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 4th. Eighteen research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $151.83.

Shares of ALXN stock opened at $157.54 on Friday. The firm has a market capitalization of $34.63 billion, a P/E ratio of 36.81, a P/E/G ratio of 0.75 and a beta of 1.33. Alexion Pharmaceuticals, Inc. has a twelve month low of $94.82 and a twelve month high of $162.60. The company has a quick ratio of 3.26, a current ratio of 3.81 and a debt-to-equity ratio of 0.22. The stock’s fifty day simple moving average is $152.69 and its 200 day simple moving average is $141.87.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, February 3rd. The biopharmaceutical company reported $2.96 earnings per share for the quarter, topping analysts’ consensus estimates of $2.56 by $0.40. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.51 billion. Alexion Pharmaceuticals had a return on equity of 23.16% and a net margin of 16.32%. Alexion Pharmaceuticals’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.71 EPS. As a group, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 11.14 EPS for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

See Also: How a Back-End Load Mutual Fund Works

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.